Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study - PubMed (original) (raw)
. 1997:11 Suppl 2:S13-21.
Affiliations
- PMID: 9236948
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study
R C Mohs et al. Alzheimer Dis Assoc Disord. 1997.
Abstract
The cognitive assessment protocol of the Alzheimer's Disease Cooperative Study (ADCS) was designed to evaluate the reliability and validity of cognitive assessment measures that might be valuable additions to the Alzheimer's Disease Assessment Scale (ADAS) or other concise batteries used in antidementia drug trials. As part of an overall ADCS protocol to develop new instruments to be used in trials of treatments for Alzheimer's disease (AD), patients with mild to moderate AD and cognitively normal elderly were administered a battery of five tests at least three times over 1 year. The tests included word list learning with delayed free recall, a recognition memory test for faces, a series of letter and digit cancellation tests to measure concentration, tests of praxis, and a series of maze completion tasks designed to assess planning and executive function. A version of the digit cancellation task was reliable and sensitive to a broad range of dementia severity so that it could provide a useful addition to the present version of the ADAS. Performance on the word learning task with delayed recall and a subset of the mazes task were impaired even in mild AD, so these tasks may be useful in trials involving mild or at-risk subjects. Performances on the facial recognition task and on the praxis tasks were not related to dementia severity, so these tasks would not be useful to evaluate treatments. Therefore, the major outcome of this investigation was the identification of some potential additions to the present ADAS that extend both the cognitive domains and the range of symptom severity covered.
Similar articles
- Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A, Hannesdottir K, Jaeger J, Annas P, Segerdahl M, Karlsson P, Sjögren N, von Rosen T, Miller F. Karin A, et al. Acta Neurol Scand. 2014 Feb;129(2):114-22. doi: 10.1111/ane.12153. Epub 2013 Jun 13. Acta Neurol Scand. 2014. PMID: 23763450 - A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study.
Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. Ferris SH, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S1-12. Alzheimer Dis Assoc Disord. 1997. PMID: 9236947 Clinical Trial. - Target symptoms and outcome measures: cognition.
Kirk A. Kirk A. Can J Neurol Sci. 2007 Mar;34 Suppl 1:S42-6. doi: 10.1017/s0317167100005552. Can J Neurol Sci. 2007. PMID: 17469681 Review. - Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Cerami C, Dubois B, Boccardi M, Monsch AU, Demonet JF, Cappa SF; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Cerami C, et al. Neurobiol Aging. 2017 Apr;52:153-166. doi: 10.1016/j.neurobiolaging.2016.03.034. Neurobiol Aging. 2017. PMID: 28317646 Review.
Cited by
- An estimate of the longitudinal pace of aging from a single brain scan predicts dementia conversion, morbidity, and mortality.
Whitman ET, Elliott ML, Knodt AR, Abraham WC, Anderson TJ, Cutfield N, Hogan S, Ireland D, Melzer TR, Ramrakha S, Sugden K, Theodore R, Williams BS, Caspi A, Moffitt TE, Hariri AR; Alzheimer’s Disease Neuroimaging Initiative. Whitman ET, et al. bioRxiv [Preprint]. 2024 Aug 22:2024.08.19.608305. doi: 10.1101/2024.08.19.608305. bioRxiv. 2024. PMID: 39229058 Free PMC article. Preprint. - Health-related resource use and costs in elderly adults with and without mild cognitive impairment.
Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Aisen PS. Zhu CW, et al. J Am Geriatr Soc. 2013 Mar;61(3):396-402. doi: 10.1111/jgs.12132. Epub 2013 Feb 15. J Am Geriatr Soc. 2013. PMID: 23414481 Free PMC article. - Language Markers of Dementia and Their Role in Early Diagnosis of Alzheimer's Disease: Exploring Grammatical and Syntactic Competence via Sentence Repetition.
Kaltsa M, Tsolaki A, Lazarou I, Mittas I, Papageorgiou M, Papadopoulou D, Tsimpli IM, Tsolaki M. Kaltsa M, et al. J Alzheimers Dis Rep. 2024 Jul 31;8(1):1115-1132. doi: 10.3233/ADR-230204. eCollection 2024. J Alzheimers Dis Rep. 2024. PMID: 39114543 Free PMC article. - Statistical Disease Progression Modeling in Alzheimer Disease.
Raket LL. Raket LL. Front Big Data. 2020 Aug 12;3:24. doi: 10.3389/fdata.2020.00024. eCollection 2020. Front Big Data. 2020. PMID: 33693397 Free PMC article. - Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
Kennedy RE, Cutter GR, Schneider LS. Kennedy RE, et al. Alzheimers Dement. 2014 May;10(3):349-59. doi: 10.1016/j.jalz.2013.03.003. Epub 2013 May 25. Alzheimers Dement. 2014. PMID: 23712001 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials